human
microsatellit
dnamimick
odn
ms
odn
compos
cct
repeat
design
studi
capac
neg
regul
innat
immun
induc
agonist
vitro
mice
result
show
could
downregul
product
cultur
human
pbmc
stimul
inactiv
flu
viru
cpg
odn
imiquimod
protect
dgalntreat
mice
lethal
shock
induc
agonist
agonist
addit
significantli
inhibit
product
purifi
human
plasmacytoid
cell
pdc
stimul
cpg
odn
interestingli
could
upregul
hladr
pdc
vitro
impli
inhibit
product
could
relat
activ
pdc
data
suggest
could
develop
candid
medica
treatment
activationassoci
diseas
inhibit
signal
pathway
viral
dna
bacteri
dna
exogen
danger
signal
immun
system
mammalian
long
time
evolut
resist
viru
bacteria
mammalian
develop
pattern
recognit
receptor
prr
sens
conserv
pathogenassoci
molecular
pattern
pamp
tolllik
receptor
tlr
sens
viral
bacteri
nucleic
acid
thereaft
initi
innat
immun
respons
viral
singlestrand
rna
ssrna
induc
larg
amount
activ
bacteri
doublestrand
dna
dsdna
activ
induc
inflammatori
cytokin
includ
synthet
nonmethyl
cpgcontain
oligodeoxynucleotid
cpg
odn
possess
similar
activ
stimul
innat
immun
bacteri
dsdna
base
stimulatori
signal
immun
system
make
decis
set
effect
respons
pathogen
toler
selfcompon
sustain
immun
homeostasi
homeostat
condit
tlr
activ
lead
protect
immun
respons
pathogen
multipl
inflammatori
pathway
incorrect
decis
made
immun
system
devast
consequ
may
occur
hostshock
short
term
autoimmun
long
term
patholog
condit
recogn
selfdna
initi
autoinn
immun
respons
sever
report
show
play
import
role
autoimmun
diseas
develop
via
activ
selfdna
cpg
odninduc
activ
also
report
capabl
induc
septic
death
due
excess
cytokinemedi
lethal
shock
dglactosamin
dgaln
sensit
mice
massiv
releas
proinflammatori
cytokin
detect
sera
mice
recent
year
outbreak
infect
sever
acut
respiratori
syndrom
coronaviru
sarscov
highli
pathogen
avian
influenza
viru
cytokin
storm
due
tlr
overactiv
viral
infect
consid
relev
high
mortal
thu
clear
control
innat
immun
overreact
could
new
approach
prevent
develop
tlr
activationassoci
diseas
differ
effort
made
develop
agent
suppress
innat
immun
overreact
provid
quit
promis
potenti
clinic
applic
treat
prevent
tlr
activationassoci
diseas
recent
year
dna
molecul
found
capabl
inhibit
tlr
activ
report
dna
fragment
deriv
calf
thymu
human
placenta
display
inhibitori
role
product
macrophag
mous
spleen
bone
marrow
thereaft
oligodeoxynucleotid
odn
mammal
telomeremimick
ttaggg
repeat
design
report
inhibit
immun
stimulatori
activ
bacteri
dna
rescu
mice
endotox
shock
block
lpsinduc
product
also
prove
therapeut
role
mice
sever
arthriti
induc
bacteri
dna
delay
onset
mous
glomerulonephr
prolong
surviv
lupuspron
nzbnzw
mice
anoth
odn
guanosinerich
sequenc
godn
identifi
block
product
inhibit
activ
mous
model
dgalncpg
odninduc
lethal
shock
moreov
odn
sequenc
design
reveal
effect
reduc
sever
clinic
symptom
lupuspron
mice
antagon
activ
structur
inhibitori
odn
introduc
grich
gcontain
repeat
sequenc
howev
still
uncertain
key
structur
featur
design
effici
inhibitori
odn
especi
select
suppress
activ
differ
tlr
laboratori
seri
microsatellit
dna
ms
dna
mimick
odn
ms
odn
design
accord
microsatellit
dna
repeat
human
genom
inhibitori
regul
innat
immun
system
human
microsatellit
dna
occupi
human
genom
highli
repetit
element
compos
nucleotid
investig
indic
genom
dna
deriv
apoptot
necrot
cell
could
uptaken
macrophag
cut
dna
fragment
dnase
ii
impli
abund
selfdna
fragment
big
part
microsatellit
dna
big
chanc
stimul
host
immun
system
howev
physiolog
condit
selfdna
fragment
unabl
initi
antiselfdna
immun
respons
immuneinhibitori
possibl
confirm
deduct
ms
odn
odn
design
sequenc
human
microsatellit
dna
observ
inhibitori
effect
immun
respons
human
pbmc
cpg
odn
stimul
vitro
found
ms
odn
tc
ttc
tttc
ttcc
tttttc
repeat
also
ct
cct
repeat
could
significantli
inhibit
cpg
odninduc
activ
impli
human
microsatellit
dnaderiv
dna
fragment
may
neg
regul
innat
immun
respons
therefor
sustain
toler
selfdna
present
studi
ms
odn
cct
repeat
design
studi
inhibitori
effect
activ
found
could
downregul
product
induc
viral
nucleic
acid
vitro
protect
mice
dgalncpg
odninduc
lethal
shock
activationmedi
death
suppress
product
human
plasmacytoid
cell
pdc
induc
cpg
odn
interestingli
could
also
activ
pdc
manifest
upregul
mhc
class
ii
costimulatori
molecul
data
suggest
could
use
potenti
candid
develop
medica
treatment
activationassoci
diseas
block
signal
nucleaseresist
phosphorothioatemodifi
odn
synthes
takara
co
dalian
china
cpg
odn
use
studi
publish
inhibitori
odn
use
studi
owndesign
odn
lowercas
capit
letter
repres
phosphorothio
phosphodiest
linkag
respect
odn
dilut
pb
test
endotoxin
use
limulu
amebocyt
lysat
assay
associ
cape
cod
inc
dgalactosamin
hydrochlorid
dgalactosamin
hcl
dgaln
purchas
debiochem
nanj
china
chloroquin
diphosph
salt
lp
actinomycin
actd
polyinosinicpolycytidyl
acid
poli
c
sigma
st
loui
mo
usa
imiquimod
lvye
chemic
co
ltd
yancheng
china
human
recombin
neptunu
interlong
biotechnolog
co
ltd
shengzhen
china
reagent
use
pyrogenfre
reagent
human
peripher
blood
mononuclear
cell
hpbmc
isol
buffi
coat
blood
center
jilin
provinc
china
ficollhypaqu
densiti
gradient
centrifug
wash
three
time
iscov
modifi
dulbecco
medium
imdm
hyclon
logan
ut
usa
viabil
pbmc
determin
trypan
blue
exclus
vero
cell
african
green
monkey
kidney
cell
line
american
type
cultur
collect
atcc
cultur
co
humidifi
incub
maintain
imdm
supplement
volvol
heatinactiv
fetal
bovin
serum
fb
antibiot
iu
penicillinml
iu
streptomycinml
cell
murin
macrophagelik
cell
line
atcc
cell
male
balbc
mous
fibroblast
cultur
co
humidifi
incub
maintain
rpmi
medium
supplement
volvol
heatinactiv
fb
antibiot
iu
penicillinml
iu
streptomycinml
human
plasmacytoid
dendrit
cell
pdc
purifi
plasmacytoid
dendrit
cell
isol
kit
miltenyi
biotec
bergisch
gladbach
germani
stain
monoclon
antibodi
bd
bioscienc
san
jose
ca
usa
analyz
fac
canto
bd
bioscienc
puriti
antivir
activ
cultur
supernat
hpbmc
mous
splenocyt
treat
differ
stimul
differ
inhibitor
measur
use
vsv
protect
assay
supernat
hpbmc
well
cultur
differ
stimul
inactiv
rna
viru
flu
viru
dna
viru
imiquimod
cpg
odn
orand
differ
inhibitor
chloroquin
h
collect
store
aliquot
use
vero
cell
well
cell
well
seed
flatbottom
plate
cultur
h
confluenc
cell
incub
supernat
h
challeng
tcid
tissu
cultur
infecti
dose
vesicular
stomat
viru
vsv
anoth
h
discard
cultur
supernat
cell
stain
crystal
violet
analyz
cytopath
effect
viru
use
multiwel
microtit
reader
nm
cytopath
level
cell
express
od
valu
activ
supernat
measur
cytotox
bioassay
assay
base
upon
cytotox
cell
briefli
cell
seed
densiti
cellswel
cultur
plate
rpmi
medium
contain
fetal
bovin
serum
incub
h
medium
well
replac
supernat
doubl
dilut
complet
cultur
medium
present
actd
incub
anoth
h
stain
crystal
violet
cytotox
cell
determin
multiwel
microtit
plate
reader
nm
express
od
valu
experiment
control
sampl
perform
triplic
eightweekold
specif
pathogenfre
spf
femal
balbc
mice
g
weight
obtain
experiment
anim
center
medic
colleg
norman
bethun
jilin
univers
given
free
access
food
water
experi
anim
experi
mice
firstli
inject
intraperiton
ip
dgaln
mg
ml
pb
h
make
becom
sensit
immun
stimul
randomli
divid
differ
group
cpg
odn
mous
pb
lp
mous
pb
poli
c
mous
pb
use
stimul
trigger
excess
cytokinemedi
lethal
shocklik
syndrom
mice
ip
inject
odn
chloroquin
also
inject
ip
either
simultan
stimul
differ
time
point
mice
surviv
mice
record
experi
conduct
accord
nation
guidelin
care
use
laboratori
anim
analyz
patholog
chang
mous
liver
liver
organ
normal
mice
dgalntreat
mice
inject
cpg
plu
fix
neutralbuff
formalin
embed
paraffin
cut
thick
affix
slide
section
stain
hematoxylin
eosin
morpholog
chang
section
liver
tissu
determin
microscopi
human
pdc
cellsml
incub
without
cpg
odn
andor
h
wash
twice
fac
stain
buffer
pb
supplement
bsa
nan
mm
edta
collect
cultur
supernat
cytokin
detect
analyz
express
hladr
stain
pelabel
hladr
mab
bd
bioscienc
san
jose
usa
follow
analysi
fac
canto
bd
bioscienc
san
jose
usa
supernat
human
pdc
store
use
analyz
bind
uptak
cell
cellsml
incub
fluoresc
min
min
cell
wash
analyz
flow
cytometri
supernat
human
pdc
store
use
determin
cytokin
elisa
kit
bender
medsystem
inc
ca
usa
r
system
minneapoli
mn
usa
use
detect
supernat
accord
manufactur
protocol
cytokin
level
supernat
quantit
calcul
base
standard
curv
data
shown
mean
standard
deviat
sd
statist
signific
differ
determin
use
pair
twotail
student
ttest
surviv
mice
compar
use
kaplanmei
test
signific
level
fix
differ
consid
statist
signific
p
b
ms
odn
cct
repeat
display
inhibitori
effect
activ
vitro
develop
potenti
therapeut
agent
treatment
autoimmun
diseas
consid
close
relationship
product
develop
autoimmun
diseas
select
type
interferon
bioassay
vsv
protect
assay
technic
platform
screen
odn
design
refer
sequenc
human
microsatellit
dna
inhibitori
effect
type
ifn
product
process
ms
odn
cct
repeat
design
found
inhibit
product
cultur
human
pbmc
stimul
agonist
determin
whether
could
block
activ
serialdilut
inactiv
rna
viru
flu
viru
agonist
use
induc
type
ifn
product
human
pbmc
antivsv
activ
supernat
agoniststimul
pbmc
compar
display
recombin
shown
figur
flu
viru
supernat
human
pbmc
could
protect
vero
cell
vsv
challeng
flu
viru
abl
induc
similar
antivir
activ
iuml
use
later
experi
test
inhibitori
effect
ifn
product
flu
viru
pbmc
human
pbmc
cultur
inactiv
flu
viru
presenc
two
posit
control
odn
neg
control
ms
odn
fro
h
supernat
assay
antivsv
activ
result
show
display
signific
inhibit
ifn
product
potenc
similar
display
much
stronger
fig
find
optim
dosag
pbmc
incub
inactiv
flu
viru
presenc
dose
rang
h
found
pbmc
differ
donor
respond
various
consist
inhibit
ifn
product
pbmc
test
blood
sampl
data
shown
upon
select
optim
dosag
later
vitro
experi
shown
figur
remark
inhibit
flu
viru
ifn
product
pbmc
seven
healthi
blood
donor
p
b
indic
antagonist
activ
anoth
set
experi
inactiv
flu
viru
replac
imiquimod
synthet
agonist
stimul
dosag
could
also
display
signific
inhibitori
effect
pbmc
produc
ifn
fig
overal
result
show
could
inhibit
activationinduc
ifn
product
test
whether
could
inhibit
ifn
product
induc
activ
inactiv
dna
viru
cpg
atyp
cpg
odn
use
stimul
shown
figur
abl
display
similar
antivir
activ
iuml
use
later
experi
found
significantli
inhibit
inactiv
ifn
product
human
pbmc
much
better
efficaci
p
fig
dosedepend
manner
fig
could
also
inhibit
cpg
ifn
product
human
pbmc
dosedepend
manner
fig
result
indic
also
block
activationinduc
ifn
product
studi
kinet
action
human
pbmc
stimul
either
inactiv
flu
viru
respect
without
addit
differ
time
point
cultur
supernat
use
vsv
protect
assay
result
show
could
significantli
inhibit
ifn
product
pbmc
activ
inactiv
flu
viru
ad
cultur
simultan
stimul
h
poststimul
fail
display
obviou
inhibitori
role
ad
h
longer
poststimul
fig
b
result
illustr
may
target
signal
molecul
agonist
affin
high
enough
replac
stimul
act
signal
molecul
afterward
supernat
human
pbmc
cultur
medium
contain
agonist
without
addit
collect
differ
time
point
assay
vsv
protect
assay
show
supernat
pbmc
stimul
inactiv
flu
viru
h
longer
could
protect
vero
cell
vsv
challeng
fail
display
protect
supernat
cell
stimul
less
h
fig
upon
inhibitori
effect
ifn
product
human
pbmc
trigger
agonist
evalu
h
stimul
observ
influenc
way
administr
inhibitori
effect
inactiv
flu
viru
premix
h
use
separ
act
human
pbmc
h
supernat
assay
vsv
protect
assay
result
show
premix
ad
simultan
inactiv
flu
viru
fig
fig
display
similar
inhibit
ifn
product
human
pbmc
compar
display
much
stronger
inhibit
p
b
fig
f
data
indic
mediat
inhibit
due
extracellular
interact
tlr
agonist
like
flu
viru
studi
inhibitori
role
innat
immun
mice
test
whether
work
function
mous
splenocyt
firstli
balbc
mousederiv
splenocyt
stimul
cpg
typic
mous
aclass
cpg
odn
presenc
h
supernat
use
protect
cell
vsv
challeng
shown
figur
could
inhibit
cpg
stimul
ifn
product
splenocyt
wherea
could
detect
whether
could
block
product
mous
macrophag
macrophag
cell
line
cell
stimul
cpg
typic
mous
bclass
cpg
odn
presenc
h
supernat
harvest
assay
product
cytotox
bioassay
result
show
could
inhibit
cytotox
supernat
cell
trigger
cpg
fig
demonstr
decreas
product
mous
immun
cell
suppress
activ
upon
vitro
analysi
evalu
vivo
effect
mous
model
excess
cytokinemedi
lethal
shock
induc
differ
tlr
agonist
creat
model
balbc
mice
presensit
dgaln
h
inject
ip
imiquimod
cpg
respect
system
imiquimod
could
induc
mice
develop
lethal
shock
even
per
dgalnsensit
mous
accordingli
dgalnsensit
mice
firstli
inject
cpg
presenc
chloroquin
antagonist
interf
acidif
endosom
surviv
mice
record
appar
shown
figur
mice
cpg
group
dead
h
contrast
mice
cpg
plu
group
mice
cpg
plu
group
mice
cpg
plu
chloroquin
group
still
aliv
h
demonstr
could
rescu
mice
excess
cytokinemedi
lethal
shock
induc
activ
notabl
could
also
partial
resist
cpg
excess
cytokinemedi
lethal
shock
mice
wherea
chloroquin
remark
expect
patholog
analysi
reveal
cpg
abl
induc
sever
liver
hemorrhag
necrosi
dgalnsensit
mice
wherea
could
prevent
patholog
chang
fig
impli
display
inhibitori
role
innat
immun
respons
activ
mediat
prevent
effect
cpg
odninduc
liver
injuri
mice
subsequ
dose
effect
resist
cpg
lethal
shock
observ
dgalntreat
mice
appar
shown
figur
mice
group
cpg
alon
plu
dead
h
wherea
mice
group
cpg
plu
three
dose
still
aliv
h
notic
fail
protect
mice
lethal
shock
induc
cpg
molar
ratio
cpg
approxim
consist
save
test
mice
fig
molar
ratio
cpg
approxim
data
suggest
could
function
compet
cpg
result
reveal
may
optim
dosag
rescu
mice
activationinduc
excess
cytokinemedi
lethal
shock
moreov
test
suitabl
time
administr
dgalncpg
mice
separ
inject
ip
dgaln
sensit
mice
h
h
cpg
inject
simultan
cpg
inject
h
h
h
cpg
inject
surviv
mice
record
result
show
could
effect
protect
mice
cpg
excess
cytokinemedi
lethal
shock
inject
h
h
simultan
cpg
inject
fail
display
protect
role
inject
h
later
cpg
inject
fig
may
hint
compet
cpg
site
target
cell
know
whether
could
also
inhibit
activ
tlr
lp
poli
c
use
stimul
induc
excess
cytokinemedi
lethal
shock
dgalntreat
mice
result
show
poli
c
lp
mous
could
induc
death
dgalntreat
mice
howev
could
rescu
dgalntreat
mice
lpsand
poli
cinduc
excess
cytokinemedi
lethal
shock
even
fig
b
may
hint
display
inhibitori
role
innat
immun
respons
select
pathway
pathway
sinc
pdc
major
cell
produc
respons
activ
next
test
whether
target
pdc
display
immun
suppress
human
pdc
purifi
buffi
coat
three
healthi
donor
puriti
determin
fac
analysi
fig
afterward
cpg
select
stimul
pdc
activ
immun
cell
produc
larg
amount
pdc
stimul
cpg
alon
presenc
h
analyz
fac
canto
express
surfac
molecul
stain
fluorescencelabel
mab
result
show
express
hladr
surfac
pdc
upregul
cpg
also
cpg
plu
activ
upregul
surfac
molecul
pdc
similar
much
higher
fig
noteworthi
lower
activ
cpg
upregul
hladr
pdc
could
due
dose
compar
odn
anoth
set
experi
effect
cytokin
product
pdc
induc
cpg
odn
also
observ
purifi
pdc
incub
cpg
presenc
h
supernat
collect
assay
elisa
shown
figur
cpg
could
stimul
pdc
produc
high
level
could
use
alon
use
togeth
significantli
inhibit
product
pdc
trigger
cpg
compar
inhibit
display
profound
display
fig
obvious
display
tendenc
could
induc
signific
inhibit
product
pdc
treat
cpg
fig
c
result
indic
target
human
pdc
cell
express
control
product
possibl
cytokin
induc
via
activ
observ
could
bind
surfac
target
cell
label
conduct
bind
uptak
assay
cell
human
plasmacytoid
dendrit
cell
pdc
line
use
describ
genet
phenotyp
featur
cell
bear
similar
pdc
cell
promin
express
also
stimul
ligand
cpg
odn
odn
cell
produc
cell
line
open
opportun
studi
pdc
vitro
refer
paper
cell
cultur
either
min
bind
experi
min
uptak
experi
two
dose
respect
analyz
flow
cytometri
shown
figur
fluoresc
intens
cell
cocultur
either
significantli
increas
dosedepend
manner
compar
medium
control
indic
bind
surfac
uptaken
cell
articl
show
human
microsatellit
dnamimick
odn
ms
odn
cct
repeat
display
inhibitori
role
activationinduc
innat
immun
respons
possibl
target
pdc
structur
primarili
differ
inhibitori
odn
report
previous
capabl
block
cpginduc
b
cell
activ
g
substitut
central
motif
suppress
activ
correl
ttaggg
repeat
form
gtetrad
ir
grich
odn
confirm
inhibit
ifn
product
pdc
respons
dna
rna
virus
moreov
replac
gcgtt
acgtt
gcggg
acggg
could
convert
stimulatori
odn
inhibitori
odn
overal
report
inhibitori
odn
g
contain
poli
g
contain
grich
previou
studi
demonstr
ms
odn
repeat
compos
c
could
effect
display
inhibitori
effect
cpg
odninduc
innat
immun
respons
vitro
present
articl
g
base
compos
cct
repeat
abund
microsatellit
dna
human
genom
notic
knowledg
first
report
show
oligonucleotid
without
g
base
capabl
inhibit
activ
andor
protect
mice
excess
cytokinemedi
lethal
shocklik
syndrom
reveal
grich
sequenc
structur
featur
inhibitori
odn
recent
report
deoxyribos
homopolym
psmodifi
backbon
act
antagonist
addit
random
dna
base
homopolym
alter
antagonist
function
qualiti
psmodifi
odn
overcom
presenc
cpg
motif
ps
cpg
odn
success
convert
high
affin
psmodifi
molecul
robust
activ
data
support
inhibitori
psmodifi
odn
without
cpg
howev
data
challeng
view
random
dna
base
affect
antagonist
activ
ps
deoxyribos
homopolym
instanc
psmodifi
could
inhibit
ifn
product
vitro
cultur
pbmc
pdc
induc
tlr
agonist
wherea
psmodifi
found
almost
inert
moreov
inhibit
product
induc
cpg
ifn
product
balbc
splenocyt
trigger
cpg
interestingli
rescu
mice
cytokinemedi
lethal
shock
although
less
potent
result
indic
psmodifi
odn
mediat
inhibit
requir
particular
motif
vitroinert
psmodifi
odn
might
inhibitori
vivo
investig
inhibitori
activ
innat
immun
ligand
firstli
select
immun
stimul
experi
system
primarili
flu
viru
rna
viru
agonist
dna
viru
agonist
use
major
stimul
vitro
experi
consid
tlr
activationassoci
cytokin
storm
relat
high
mortal
viral
infect
sar
avian
flu
found
could
significantli
inhibit
human
pbmc
produc
type
ifn
via
activ
induc
inactiv
flu
viru
well
human
pdc
produc
trigger
agonist
indic
could
show
promis
prospect
develop
medic
control
activationmedi
innat
immun
overreact
cytokin
storm
specul
support
vivo
data
could
rescu
dgalntreat
mice
excess
cytokinemedi
lethal
shock
trigger
agonist
involv
cytokinemedi
lethal
shock
firstli
reveal
evid
rapid
product
macrophag
toxic
shock
induc
dgaln
sensit
mice
dna
prepar
gramposit
neg
bacteria
synthet
oligonucleotid
vitro
experi
show
inhibit
product
cell
balbc
mous
macrophag
cell
line
well
pdc
one
blood
donor
report
induc
excess
hepatocyt
apoptosi
cell
sensit
dgaln
patholog
analysi
show
protect
mice
liver
injuri
dgalnsensit
mice
induc
cpg
odn
impli
might
inhibit
develop
excess
cytokinemedi
lethal
shocklik
syndrom
suppress
liver
injuri
trigger
activ
addit
might
also
involv
develop
excess
cytokinemedi
lethal
shocklik
syndrom
stimul
vaccin
found
prime
determin
greater
magnitud
vaccineinduc
immun
respons
human
case
infect
influenza
viru
excess
cytokinemedi
lethal
shocklik
syndrom
character
higher
plasma
level
cytokin
observ
patient
particularli
patient
fatal
infect
consid
possibl
involv
influenza
viru
induc
hypercytokinemia
data
inhibit
cytokin
product
induc
flu
viru
agonist
might
specul
could
inhibit
develop
excess
cytokinemedi
lethal
shock
influenza
virusinfect
patient
establish
cpg
odn
agonist
imiquimod
flu
viru
agonist
data
show
articl
demonstr
could
significantli
inhibit
ifn
product
pbmc
stimul
cpg
odn
imiquimod
flu
viru
purifi
human
pdc
stimul
cpg
odn
indic
might
use
antagonist
downregul
activationassoci
diseas
accompani
highlevel
product
ifn
recent
year
pathway
implic
contribut
develop
inflammationassoci
diseas
autoimmun
diseas
report
show
mice
use
graft
recipi
allogen
bone
marrow
thransplant
surviv
clinic
score
acut
graftvshost
diseas
gvhd
effici
improv
compar
wildtyp
mice
suggest
activ
contribut
gvhd
manner
immun
complex
ic
consist
autoantibodi
specif
selfdna
rna
induc
pdc
produc
high
level
promot
progress
system
lupu
erythematosu
abnorm
product
pdc
activ
involv
develop
psoriasi
syndrom
type
diabet
hashimoto
diseas
dermatomyos
bind
uptak
cell
cell
cultur
medium
without
either
min
min
follow
wash
three
time
analyz
facscan
result
express
mean
fluoresc
intens
mfi
repres
data
one
three
experi
shown
demonstr
chronic
trigger
mice
use
ligand
lead
immun
activ
disrupt
lymphoid
architectur
similar
observ
chronic
infect
human
taken
togeth
find
also
prompt
us
develop
medica
treatment
activationassoci
diseas
block
signal
data
articl
suggest
function
interf
tlr
signal
rather
bind
tlr
ligand
directli
use
mous
model
found
administr
h
stimul
cpg
still
save
mice
die
excess
cytokinemedi
lethal
shocklik
syndrom
addit
cpg
odn
also
inhibit
product
induc
inactiv
agonist
flu
viru
agonist
obvious
bind
virus
directli
analysi
provid
group
also
exclud
possibl
godn
inhibitori
odn
administ
h
stimul
cpg
godn
still
inhibit
activationinduc
secret
upregul
major
histocompat
complex
mhc
class
ii
costimulatori
molecul
inhibitori
odn
ad
endotheli
leukocyt
adhes
molecul
gene
transfect
cell
h
prior
cpg
odn
could
interf
uptak
cpg
odn
interestingli
found
cpg
could
upregul
express
hladr
surfac
human
purifi
pdc
seemingli
inhibit
product
pdc
somehow
depend
upregul
surfac
molecul
pdc
word
presum
inhibitori
effect
product
result
kind
activ
pdc
